Citations

Clear

623 citation(s) found for "Torres, V".

Primary Cutaneous Anaplastic Large Cell Lymphoma With TCR‐γδ Expression: A Case Series of Eleven Patients of a Rare Immunophenotypic Variant
Erem, Anna Sarah , Mitteldorf, Christina , Pulitzer, Melissa , Rodríguez-Pinilla, Socorro Marıá , Feldman, Andrew L. , Gru, Alejandro A. , Pulitzer, Melissa , Torres-Cabala, Carlos , Feldman, Andrew L , Gru, Alejandro , Kempf, Werner , Torres‐Cabala, Carlos A. , Pileri, Stefano

Mayo Clinic

Journal of Cutaneous Pathology | April 9, 2025 | Volume: 52 | Issue: 7 | Pages: 487-496

10.1111/cup.14809 | PMID 40202044 Get It

ABSTRACTBackgroundPrimary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis (LyP) are indolent CD30‐positive lymphoproliferative disorders that rarely express TCR‐γδ. However, primary cutaneous gamma‐delta T‐cell lymphoma (pcGDTCL), characterized by TCR‐γδ expression on neoplastic cells, is a rare, aggressive cutaneous T‐cell lymphoma with a poor prognosis. Accurate differentiation is essential due to distinct clinical behavior and treatment.MethodsWe identified 11 TCR‐γδ‐positive pcALCL cases from internal and consultation files, verified by two cutaneous lymphoma experts, with clinicopathologic data recorded.ResultsThe median age was 68 years (range 38–95). Most cases presented as a single dermal lesion on the upper extremities. All were ALK‐negative, CD30‐positive (> 90% tumor cells), TCR‐βF1‐negative, and diffusely TCR‐γδ‐positive. CD4−/CD8− (54.5%) and CD4+/CD8− (45.5%) immunophenotypes were observed. CD2 (63.6%) and CD3 (54.5%) were the most common T‐cell antigens. Ulceration, inflammation (both 45.5%), and necrosis (36.4%) were frequent. Angiotropism, angiocentricity, and myxoid stroma appeared in one case; epidermotropism in two. Four of ten tested were DUSP22‐rearranged, and TP63 was negative in all eight tested.ConclusionsMost ALK‐negative TCR‐γδ‐positive pcALCL were CD4−/CD8−, followed by CD4+/CD8−. DUSP22 rearrangement occurred in 40% of cases, similar to reports in typical pcALCL. Its prognosis and the role of DUSP22 are yet to be clarified.
Recurrence of a Chondroid Tenosynovial Giant Cell Tumor in the Temporomandibular Joint (P9-6.013)
Khawaja, Anusha, Lanzino, Guiseppe, Torres‐Mora, Jorge , Folpe, Andrew, Khawaja, Anusha, Johnson, Derek R. , Sener, Uğur

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208461 Get It

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Leading with options or issues to support purposeful shared decision-making in clinical practice
Loor-Torres, Ricardo , Bui, Yvonne , Steffensen, Karina Dahl , Heen, Anja Fog , Agoritsas, Thomas , Kunneman, Marleen , Carley, Meg , Cabezas, Esteban , Stacey, Dawn , Hargraves, Ian , Carley, Meg E , Montori, Victor M , Stacey, Dawn , Montori, Víctor M.

Mayo Clinic

BMJ Evidence-Based Medicine | April 1, 2025 | Volume: 30 | Issue: 6 | Pages: 409-412

10.1136/bmjebm-2024-113322 | PMID 40169187 Get It

The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Hanauer, Stephen B. , Torres, Esther A. , Aragon-Han, Patricia, Chapman, J. Casey, Arai, Ronen, Butnariu, Mandalina, Lee, Thomas C., Rabizadeh, Shervin , Check, Morgan, Hashash, Jana G. , Meister, Thomas, Yen, Eugene F. , Kinnucan, Jami , Ziring, David , Shaposhnikov, Rimma, Sinh, Preetika , Qazi, Taha , Yarur, Andrés , Monzur, Farah , Abraham, Bincy , Lee, Thomas C , Hashash, Jana G , Sinh, Preetika , Abraham, Bincy P , Yarur, Andres J , Hanauer, Stephen B , Swaminath, Arun C. , Butnariu, Mandalina, Barrett, Terrence A. , Stein, Daniel J., Shaposhnikov, Rimma, Dervieux, Thierry

Mayo Clinic

Pharmaceutics | March 28, 2025 | Volume: 17 | Issue: 4 | Pages: 428

10.3390/pharmaceutics17040428 | PMID 40284422 Get It

Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD). Methods: In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression. Results: A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively. Conclusions: PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.
Autosomal Dominant Polycystic Kidney Disease
Hanna, Christian , Dahl, Neera K. , Hanna, Christian , Dahl, Neera K , Chebib, Fouad T. , Harris, Peter C. , Torres, Vicente E.

Mayo Clinic

JAMA | March 24, 2025 | Volume: 333 | Issue: 19 | Pages: 1708

10.1001/jama.2025.0310 | PMID 40126492 Get It

Importance Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive development of kidney cysts and is the most common inherited kidney disorder worldwide. ADPKD accounts for 5% to 10% of kidney failure in the US and Europe, and its prevalence in the US is 9.3 per 10 000 individuals. Observations ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes. Most persons with ADPKD have an affected parent, but de novo disease is suggested in 10% to 25% of families. More than 90% of patients older than 35 years have hepatic cysts, which may cause abdominal discomfort and occasionally require medical or surgical intervention. Hypertension affects 70% to 80% of patients with ADPKD, and approximately 9% to 14% develop intracranial aneurysms, which have a rupture rate of 0.57 per 1000 patient-years. Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age. The severity of kidney disease can be quantified using the Mayo Imaging Classification (MIC), which stratifies patients based on total kidney volume adjusted for height and age and ranges from 1A to 1E. Patients with MIC 1C to MIC 1E have larger kidneys because of more rapid growth (6%-10% per year) compared with those with MIC 1A and 1B (1%-5% per year) and have earlier progression to kidney replacement therapy, which occurs at a mean age of 58.4 years for MIC 1C, 52.5 years for MIC 1D, and 43.4 years for MIC 1E. Optimal management of ADPKD includes systolic blood pressure lower than 120 mm Hg for most patients, but lower than 110/75 mm Hg for patients with MIC 1C to 1E who have an estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m 2 and are younger than 50 years, dietary sodium restriction (&amp;lt;2000 mg/d), weight management, and adequate hydration (&amp;gt;2.5 L daily). The vasopressin type 2 receptor antagonist tolvaptan reduces the annual rate of eGFR decline by 0.98 to 1.27 mL/min/1.73 m 2 and is indicated for patients with MIC 1C to 1E or an eGFR decline greater than 3 mL/min/1.73 m 2 per year to slow disease progression and delay the onset of kidney failure. Conclusion ADPKD is the most common genetic kidney disease worldwide and is characterized by progressive development of kidney cysts. Patients typically have hypertension and liver cysts, and 9% to 14% develop intracranial aneurysms. First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration. Tolvaptan reduces the rate of eGFR decline for those at high risk of rapid progression to kidney failure.
Pattern of Long-Term Intraocular Pressure Variation Following Gonioscopy-Assisted Transluminal Trabeculotomy: Two-Year Outcomes
Faria, Bruno M. , Dias, Diego Torres , Reis, Maria Clara dos , Daga, Fábio B. , Scoralick, Ana Luiza Bassoli , Magacho, Leopoldo , Junior, Pedro H.E. Ribeiro, Kanadani, Fábio Nishimura , Costa, Vital Paulino , Kanadani, Fábio N., Junior, Pedro H.E. Ribeiro, Prata, Tiago S.

Mayo Clinic

Journal of Glaucoma | March 12, 2025 | Volume: 34 | Issue: 8 | Pages: 630-636

10.1097/ijg.0000000000002565 | PMID 40071986 Get It

Précis: Patients with clinically uncontrolled open angle glaucoma submitted to isolated gonioscopy-assisted transluminal trabeculotomy or combined with phacoemulsification not only achieved low mean IOPs, but also demonstrated stable IOP patterns during a 24-month follow-up. Purpose: To assess the impact of gonioscopy-assisted transluminal trabeculotomy (GATT) on long-term intraocular pressure (IOP) variation. Patients and Methods: An unicentric retrospective study including 169 consecutive patients who had undergone standalone GATT or combined with phacoemulsification (PHACOGATT) due to clinically uncontrolled open angle glaucoma, with at least 12 months of follow-up was conducted. Long-term mean IOP, long-term IOP peak, long-term IOP fluctuation, coefficient of variation, mean-positive IOP variation, sustained clinically significant positive IOP variation, and number of follow-up visits with IOP ≥15 mm Hg were investigated. Results: One hundred sixty-nine eyes from 169 patients were included (GATT group=101 patients; PHACOGATT group=68 patients). Mean long term IOP (12.0±1.8 vs. 11.2±2.0 mm Hg), mean long-term IOP peak (12.9±2.6 vs. 11.8±3.5 mm Hg), and mean coefficient of variation (0.07±0.08 vs. 0.05±0.09) were lower in the PHACOGATT group, while mean IOP fluctuation (1.0±3.7 vs. 1.2±1.8 mm Hg) was lower in the GATT group. In addition, the overall mean-positive IOP variation was 0.79±1.64 mm Hg. Finally, only 6.5% of the patients presented sustained clinically significant positive IOP variation and IOP was ≥15 mm Hg in 5.9% of the follow-up visits. Conclusions: Patients with clinically uncontrolled open angle glaucoma submitted to GATT or PHACOGATT achieved low mean IOPs and demonstrated stable IOP patterns. Our results provide additional evidence supporting GATT and PHACOGATT as viable options for the treatment of medically uncontrolled glaucoma patients requiring low and stable IOPs.
Effect of an Interdisciplinary CKD Clinic on Disease Progression, Health Care Use, and Social Determinants of Health
Chavez, Maria Mateo , Moran-Melendez, Andrea, Salter, Lucy , Vaughan, Lisa E. , Loor-Torres, Ricardo , Albright, Robert C. , Manohar, Sandhya , Zoghby, Ziad , Kattah, Andrea G. , Suarez, Maria Lourdes Gonzalez , Hines, Vicky L., Gonzalez, Daniel A , Bandi, Satya Sai Sri, Boehmer, Kasey R. , Mateo Chavez, Maria B , Vaughan, Lisa , Loor-Torres, Ricardo J , Albright, Robert, Kattah, Andrea G , Gonzalez Suarez, Maria L , Rose, Katie, Hines, Vicky , Gonzalez-Mosquera, Daniel A , Bandi, Satya Sri , Boehmer, Kasey R , El-Zoghby, Ziad , Salter, Lucy , Rose, Katie

Mayo Clinic

Kidney360 | February 18, 2025 | Volume: 6 | Issue: 6 | Pages: 937-946

10.34067/kid.0000000734 | PMID 39964760 Get It

Key Points Patient-centered care in an interdisciplinary CKD clinic addresses complex needs and supports comprehensive CKD management. Implementation of an interdisciplinary CKD clinic reduced hospital admissions by 26%, emergency department visits by 30%, and increased nephrology consultations. Comprehensive care models with integrated registries enhance tailored interventions, leading to improved CKD management outcomes. Background CKD is a significant public health issue globally. Its progressive nature calls for innovative care models to mitigate disease progression and enhance patient outcomes. An interdisciplinary clinic model may offer comprehensive care tailored to the needs of patients with CKD. The aim of this study was to evaluate the effect of an interdisciplinary CKD clinic on disease progression, health care utilization, and social determinants of health (SDOH). Methods We conducted a retrospective cohort study at the Mayo Clinic in Rochester, Minnesota. The study included 534 patients enrolled in the CKD clinic between March 5, 2021, and May 31, 2022, excluding those who opted out of research. The intervention involved a clinical registry and an interdisciplinary team delivering evidence-based care pathways, patient education, shared decision making, and care coordination. The primary outcomes assessed were CKD progression and health care utilization, while secondary outcomes examined the effect of SDOH. Results At entry, the median age was 73 (interquartile range, 64–79) years, with 60% at stage 4 or lower. Clinic implementation correlated with a 26% decrease in hospital admissions (incidence rate ratio [IRR], 0.74; 95% confidence interval [CI], 0.60 to 0.91; P = 0.004) and a 30% reduction in emergency visits (IRR, 0.70; 95% CI, 0.57 to 0.87; P = 0.001). Nephrology consultations increased by 46% (IRR, 1.46; 95% CI, 1.34 to 1.60; P < 0.001), reflecting enhanced specialized care. Lower exercise frequency and unemployment were linked to increased CKD progression and health care usage. Conclusions An interdisciplinary CKD clinic supported by a registry can potentially reduce health care utilization among patients with CKD, with SDOH playing a critical role in disease management.
Raver1 links Ripk1 RNA splicing to caspase-8-mediated pyroptotic cell death, inflammation, and pathogen resistance
Zhang, Boyao , Ørning, Pontus , Lehman, Jesse , Dinis, Alexandre , Torres-Ulloa, Leslie , Elling, Roland , Kelliher, Michelle A. , Bertin, John , Proulx, Megan K. , Goguen, Jon D. , Ryan, Liv , Kandasamy, Richard K. , Espevik, Terje , Lien, Egil , Lehman, Jesse W , Pai, Athma A , Fitzgerald, Katherine A , Lien, Egil , Kandasamy, Richard K

Mayo Clinic

Proceedings of the National Academy of Sciences | February 13, 2025 | Volume: 122 | Issue: 7 | Pages: No page available

10.1073/pnas.2420802122 | PMID 39946533 Get It

Multiple cell death and inflammatory signaling pathways converge on two critical factors: receptor-interacting serine/threonine kinase 1 (RIPK1) and caspase-8. Careful regulation of these molecules is critical to control apoptosis, pyroptosis, and inflammation. Here, we found a pivotal role of Raver1 as an essential regulator of Ripk1 pre-mRNA splicing, expression, and functionality and the subsequent caspase-8-dependent inflammatory cell death. We show that Raver1 influences mRNA diversity primarily by repressing alternative exon inclusion. Macrophages from Raver1 -deficient mice exhibit altered splicing of Ripk1 . As a result, Raver1 -deficient primary macrophages display diminished cell death and decreased interleukin-18 and interleukin-1ß production, when infected with Yersinia bacteria, or by restraining TGF-ß-activated kinase 1 or IKKβ in the presence of lipopolysaccharide, tumor necrosis factor family members, or interferon-γ. These responses are accompanied by reduced activation of caspase-8, Gasdermin D and E, and caspase-1 in the absence of Raver1 . Consequently, Raver1 -deficient mice showed heightened susceptibility to Yersinia infection. Raver1 and RIPK1 also controlled the expression and function of the C-type lectin receptor Mincle. Our study underscores the critical regulatory role of Raver1 in modulating innate immune responses and highlights its significance in directing in vivo and in vitro inflammatory processes.
Primary Cutaneous Spindle Cell Sarcoma With FN1::FGFR1 Fusion
Torres‐Mora, Jorge , Torres-Mora, Jorge, Shah, Ahmed, Lo, Ying‐Chun

Mayo Clinic

Journal of Cutaneous Pathology | February 13, 2025 | Volume: 52 | Issue: 5 | Pages: 353-361

10.1111/cup.14794 | PMID 39945063 Get It

ABSTRACT We report a case of a primary cutaneous spindle cell sarcoma (SCS) with FN1 :: FGFR1 fusion. The tumor lacked the typical histologic and immunohistochemical features associated with other FN1 ‐rearranged neoplasms, such as phosphaturic mesenchymal tumors (PMT) and calcified chondroid mesenchymal neoplasms (CCMN). Unlike PMTs, which often feature a cartilaginous matrix and are associated with tumor‐induced osteomalacia (TIO), the present case lacked these characteristics and did not show FGF23 mRNA expression. Immunohistochemically, the tumor cells showed patchy staining for CD34 but were negative for markers such as ERG, desmin, S100, and pan‐TRK. The fusion event in this case involves the loss of the FGFR1 Ig1 (D1) domain, a mechanism proposed to drive oncogenesis by releasing FGFR1 from autoinhibition. Despite the preservation of other FGFR1 domains, no evidence of FGF23 signaling was detected, and the patient had no clinical history of TIO. This case underscores the complexity of oncogenesis in FN1 :: FGFR1 ‐rearranged neoplasms, a form of “promiscuous” gene fusion, where similar fusions lead to diverse tumor phenotypes. It emphasizes the importance of incorporating molecular testing in diagnosing spindle cell sarcomas, particularly those occurring in acral sites, to identify this underrecognized entity.